Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 29Other hematologic neoplasm 10Thoracic 8Gastrointestinal 7CNS 7Plasma cell 6Head & Neck 5Tumor-Agnostic 4Lymphoid 4Endocrine 4Myeloid 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × trametinib × Tumor-Agnostic × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1/2 Terminated
9 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Novartis

Phase 2 Terminated
159 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01231581 2013-09-26

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

GlaxoSmithKline

Phase 2 Completed
160 enrolled 14 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡